Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Tecvayli
Tecvayli has been authorised by the EMA for multiple myeloma.
-
EMA approval · 2026-08-26EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
EMA authorised Blenrep (belantamab mafodotin) for multiple myeloma, with GSK as the marketing authorisation holder.
-
EMA approval · 2026-08-26EMA Authorised: Darzalex (daratumumab)
Daratumumab (Darzalex) has been authorised by the EMA for its indicated use in multiple myeloma.
-
EMA approval · 2026-08-26EMA Authorised: Neofordex (dexamethasone) — THERAVIA
NEOFORDEX (dexamethasone) has been authorised for use in the European market by THERAVIA for multiple myeloma.
-
EMA approval · 2026-08-07EMA Authorised: Tecvayli
Tecvayli has been authorised in the EU for multiple myeloma with conditional approval.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-05EMA Authorised: Nexpovio (selinexor) — Stemline Therapeutics B.V.
Nexpovio (selinexor) has been authorised by the EMA for therapeutic use, with multiple myeloma as a indicated disease area.
-
EMA approval · 2026-08-05EMA Authorised: Ninlaro (ixazomib citrate) — Takeda Pharma A/S
Ninlaro (ixazomib citrate) has been authorised in the EU for multiple myeloma by Takeda Pharma A/S.
-
EMA approval · 2026-08-05EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.
Kyprolis (carfilzomib) has been authorised by the EMA for multiple myeloma, with accelerated assessment.
-
EMA approval · 2026-07-22EMA Authorised: Plerixafor Accord (Plerixafor) — Accord Healthcare S.L.U.
The EMA authorises Plerixafor Accord for use in multiple myeloma and hematopoietic stem cell transplantation with Accord Healthcare S.L.U. a…
-
EMA approval · 2026-07-21EMA Authorised: Darzalex (daratumumab)
EMA authorised Darzalex (daratumumab) for use in multiple myeloma with orphan designation and accelerated assessment.
-
EMA approval · 2026-07-10EMA Authorised: Neofordex (dexamethasone) — THERAVIA
European Medicines Agency authorised Neofordex (dexamethasone) for therapeutic use, with THERAVIA as the marketing authorization holder, in …
-
EMA approval · 2026-07-07EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
EMA authorises Sarclisa (isatuximab) for multiple myeloma, expanding treatment options in this area.
-
EMA approval · 2026-06-24EMA Authorised: Tecvayli — Janssen-Cilag International N.V.
The EMA has authorised Tecvayli (Janssen-Cilag) for multiple myeloma under conditional approval.
-
EMA approval · 2026-06-12EMA Authorised: Lenalidomide Mylan (lenalidomide) — Mylan Pharmaceuticals Limited
Lenalidomide Mylan has been authorised in the EU for use in multiple myeloma.
-
EMA approval · 2026-06-09EMA Authorised: Sarclisa (Isatuximab) — Sanofi Winthrop Industrie
EMA authorises Sarclisa (isatuximab) for multiple myeloma.
-
EMA approval · 2026-06-09EMA Authorised: Neofordex (dexamethasone) — THERAVIA
EMA authorises Neofordex (dexamethasone) for multiple myeloma under THERAVIA.
-
EMA approval · 2026-04-28EMA Authorised: Darzalex (daratumumab) — Janssen-Cilag International N.V.
Authorised status for Darzalex (daratumumab) in the European Union for multiple myeloma with accelerated assessment and orphan designation.
-
EMA approval · 2026-04-24EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.
EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cance…
-
EMA approval · 2026-04-16EMA Authorised: Zolsketil pegylated liposomal (doxorubicin hydrochloride, liposomal) — Accord Healthcare S.L.U.
The EMA authorised Zolsketil pegylated liposomal doxorubicin for ovarian cancer, Kaposi sarcoma, and multiple myeloma. The Marketing Authori…
-
EMA approval · 2026-04-09EMA Authorised: Neofordex (dexamethasone) — THERAVIA
The European Medicines Agency has authorised Neofordex, a dexamethasone product from THERAVIA, for use in the treatment of multiple myeloma …
-
EMA approval · 2026-04-09EMA Authorised: Darzalex (daratumumab) — Janssen-Cilag International N.V.
The EMA authorised Darzalex (daratumumab) by Janssen-Cilag International N.V. for multiple myeloma, with orphan medicine status and accelera…
-
EMA approval · 2026-04-08EMA Authorised: Blenrep (belantamab mafodotin) — GlaxoSmithKline Trading Services Limited
The European Medicines Agency has authorised Blenrep (belantamab mafodotin) for the treatment of multiple myeloma. The decision date is 05 F…
-
FDA approval · 2026-03-25FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) filed by U.S. Pharmaceuticals.
-
EMA approval · 2026-03-25EMA Authorised: Bortezomib Accord (bortezomib) — Accord Healthcare S.L.U.
EMA authorised Bortezomib Accord for the treatment of multiple myeloma; the product is marketed by Accord Healthcare S.L.U. with a decision …
-
EMA approval · 2026-03-13EMA Authorised: Carvykti (ciltacabtagene autoleucel) — Janssen-Cilag International NV
EMA has authorised Carvykti (ciltacabtagene autoleucel) for the treatment of multiple myeloma. The product is a CAR-T therapy developed by J…